| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -34,264 | -26,095 |
| Depreciation and amortization | 379 | 274 |
| Accretion of debt discount and debt issuance costs | 714 | 465 |
| Stock-based compensation expense | 10,505 | 8,085 |
| Allowance (benefit) for credit losses | 28 | 61 |
| Provision (benefit) for excess and obsolete inventories | -3 | -24 |
| Noncash operating lease expense | 368 | 241 |
| Loss on disposal of property and equipment | -4 | - |
| Noncash loss on debt extinguishment | 0 | 0 |
| Accounts receivable | -1,014 | -1,112 |
| Inventory | 1,656 | -135 |
| Prepaid expenses and other current assets | 926 | -201 |
| Other noncurrent assets | 134 | -73 |
| Accounts payable | 50 | 385 |
| Accrued compensation | -3,488 | -4,453 |
| Accrued and other current liabilities | -458 | 392 |
| Other noncurrent liabilities | 0 | 0 |
| Net cash used in operating activities | -27,867 | -19,148 |
| Purchases of property and equipment | 380 | 210 |
| Net cash used in investing activities | -380 | -210 |
| Net proceeds from hercules loan agreement | 0 | 0 |
| Repayment of prior loan agreement | 0 | 0 |
| Debt issuance costs | 0 | 0 |
| Proceeds from employee stock purchase plan purchases | 433 | 434 |
| Taxes paid on net share settlement of restricted stock units | -55 | -54 |
| Proceeds from exercise of common stock options | 148 | 121 |
| Net cash provided by (used in) financing activities | 526 | 501 |
| Net change in cash, cash equivalents, and restricted cash | -27,721 | -18,857 |
| Cash and cash equivalents at beginning of period | 120,357 | - |
| Cash and cash equivalents at end of period | 92,636 | - |
Sight Sciences, Inc. (SGHT)
Sight Sciences, Inc. (SGHT)